THE
ARCHIVES

Week of Nov 16th, 2026 This week's theme is that what you can measure from the outside, like how fast you walk or how dense your bones are, tells you a lot about what is happening underneath. We cover what GLP-1 drugs may do to bone, a new way to make aging cells easier to clear, a brain signal hiding in your walking speed, and a surprising lung and survival signal for tirzepatide. One of the four is Travis's favorite this week. Four findings, graded honestly. Here is what is

Week of November 9th, 2026 This week is about early risk signals and what actually moves them. A Taiwanese cohort of 3.3 million adults links GLP-1 drugs to fewer aortic aneurysms, with a catch. NHANES data tie methyl-donor nutrients to lower odds of frailty. A 418-person study shows oxidized cell-free DNA changing across life and levelling off around age 45. And a paired-biopsy study asks whether liver scarring can actually reverse, this is our favorite this week. Four findi

Week of November 2nd, 2026 This week is about what actually moves the needle on aging and what only looks like it does. A phase 3 topline shows retatrutide more than doubling semaglutide's weight loss in type 2 diabetes. A Cell paper puts calorie restriction and the mutation theory of aging to the test. A huge dog cohort maps what predicts a longer life, and a centenarian study asks whether a common antibody problem stops climbing in the oldest old. One of the four is our fav

Week of October 26th, 2026 This week's theme is the gap between a headline and the people who were actually measured. A chemotherapy-free leukemia regimen beat the standard of care in a 236-patient phase 3 trial, which is about as clean as clinical evidence gets. A blood metabolome clock built on 18,476 people predicted disease and death, but it is nowhere near a test you can order. Inflammation markers start drifting upward in the 20s and 30s, a Karolinska cohort shows fitne

Week of October 12th, 2026 This week's theme is the distance between a signal and a recommendation. A senolytic combination reversed liver scarring in a small randomized trial, and a direct AMPK activator stretched lifespan in three invertebrate species, but both come with real asterisks. A Karolinska review sorted the GLP-1 safety conversation into what is established and what is still noise, while a Tufts pilot asked what to do when people stop the drug and the weight retur

Week of October 5th, 2026 This week's data keeps asking the same question from different angles: how much of aging is already happening before you feel a thing, and how much of it still answers to something you control? We open with our favorite update for the week. The largest imaging study yet of how early arterial plaque actually builds, then a global tally of how many cancers trace back to ordinary infections (which one comes in first?), a twist on epigenetic-clock scienc

Week of September 28th, 2026 This week keeps circling the same question: when does a modest signal deserve a large response? We open with an uncomfortable finding for anyone who takes glucosamine for joint pain, and pair it with a genuinely hopeful mechanism behind the weak handshake of old age, a nerve-muscle failure point that a drug can partially reverse. Then a dose of the good kind of humility: a huge meta-analysis walking back decades of mammogram overdiagnosis fear, fr

Week of September 21st, 2026. A single-cell map of the human hippocampus shows the brain's original immune cells being replaced by more inflammatory ones between ages 50 and 75. Plus a four-week randomized feeding trial that moved biological age in adults 65 to 75, the astrocyte protein behind APOE4's leaky blood-brain barrier, CREST-2's negative cognitive result, an immune sensor that misreads your own DNA as viral, and a liquid biopsy with 86.8% sensitivity for early pancre

Week of September 14th, 2026. Semaglutide started in old mice extended median lifespan by roughly 12% and beat matched calorie restriction on memory and glucose. Plus the checkpoint senescent cells use to evade immune clearance, the first genome-wide evidence that diet slows mutation accrual, why an Alzheimer's blood test only reads properly alongside APOE, a clean negative heart failure trial, chemotherapy's mutational cost in a child's liver, and the stem cell behind lumbar

Week of September 7th, 2026 The thread running through this week's research is subtraction: things your body quietly stops making, stops clearing, or starts making in the wrong place. We lead with a first-in-human trial in which a single injection knocked lipoprotein(a) down by up to 97% and held it there for nearly a year, then the phase 3 outcomes trial that spent seven years asking whether lowering that number actually prevents heart attacks and came back with an answer no

Week of August 31st, 2026 The thread running through this week's research is stubbornly consistent: aging looks less like machinery wearing out and more like an immune system that never quite stands down, and the interventions that matter are the ones that quiet it. We cover a Yale team that traced the anti-aging benefit of calorie restriction to a single immune protein made in your belly fat, a natural experiment from postwar Britain showing that sugar exposure before your s

Week of August 24th, 2026 The thread running through this week's research is size: not whether something works, but how much, and how much of the headline number survives contact with an honest analysis. We cover a Swedish screening program that separates the benefit of getting the invitation from the benefit of actually mailing the kit back, autopsy data that complicates twenty years of warnings about estrogen and dementia, a genomic detective story showing that immune cells

Week of August 17th, 2026 This week the research keeps pointing back to the body's own machinery: the hormones, brain rhythms, membrane lipids, and social wiring you already have, and how much of aging turns on whether they hold up. We cover a randomized trial testing whether semaglutide can quiet heavy drinking, a wearable study suggesting three minutes of daily huffing-and-puffing lowers cancer risk as much as an hour and a half of strolling, and a thymus hormone called thy

Week of August 10th, 2026 The thread running through this week’s research is granularity: the field keeps zooming in, from whole organs down to single cells and single molecules, and finding that the action is at the fine scale. We cover a Stanford peptide just twelve amino acids long that curbs appetite like semaglutide but skips the nausea, a Wistar discovery that a common dietary sugar acts as a chemical "get loose and spread" signal to cancer cells, and a bioengineered ch

Week of August 3, 2026 There's a quiet theme running through this week's research: the things we assume are helping us often do less than the label promises, and the ordinary inputs we treat as trivial — an hour of sleep, a museum ticket, the plastic in our water, the coffee already in our hands — may matter more than the supplements we spend money on. A landmark heart study finds micro- and nanoplastics far more often in the blood of people mid-heart-attack than in healthy a

Week of August 3, 2026 This week's research focuses one idea: the assumed culprit is often not the real one, and catching a problem before it declares itself beats treating it after. A first-in-human vaccine intercepts pancreatic cancer in high-risk patients before a tumor ever forms, while a University of Kentucky team found that Alzheimer's sleep loss comes not from amyloid plaques but from the brain's own immune cells overreacting to them. A $100 million trial is testing w

This week: precision-matched GLP-1 therapy, a biological heart-age biomarker, a new Parkinson's inflammaging mechanism, a stool-based colorectal cancer signature, what diet actually does to senescent cells, a mitochondria-peroxisome longevity link, and a gut-microbiome frailty predictor in older women. Evidence-graded, seven findings, no filler.

Week of July 20th, 2026 This week's research keeps circling one divide: the distance between a beautiful mechanism and something you can actually do on Monday morning. We cover a major trial that finally gives the other half of kidney patients a drug that works, fresh epigenetic-clock data suggesting semaglutide nudges biological aging, and a "longevity diet" whose trick turns out to be raising your own growth hormone and GLP-1 rather than cutting protein wholesale. Plus: why

Week of July 10th, 2026 This week’s research keeps circling one theme: the difference between what sounds actionable and what actually is. We dig into the blood chemistry that sets centenarians apart (and why you can’t supplement your way to it), a molecular “switch” that explains how exercise reverses muscle aging, with a catch about timing that should change how you think about training in midlife, and a head-to-head trial on whether intermittent fasting really beats calori

Seven things worth reading this week: four on longevity and health, three on performance and fitness. We spent last week on the GLP-1 wave, so this week we sit that one out. What's left is arguably more useful anyway — the levers you can actually pull. Longevity & Health 1. What your "biological age" actually means Biological-age tests are everywhere now, a swab, a fee, and a number that says you're "really" 47 or 61. This overview steps back and asks the harder question: are